[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Imperial College London\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":696},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,134,0,25,[9,59,88,117,144,174,197,229,253,279,308,334,359,379,405,432,464,493,529,549,581,612,631,649,674],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":31,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100645369","phase-2-role-of-a-mitochondrial-receptor-in-blood-sugar-regulation-100645369",false,"NCT07682233","Role of a Mitochondrial Receptor in Blood Sugar Regulation","An Experimental Medicine Study to Investigate the Role of the 18 kiloDalton Translocator Protein in Glucose Metabolism","G-TSPO","Inclusion Criteria:\n\n* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n* Aged 18-75 years old\n* A female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day) and willing to use one of the contraception methods.\n* Male subject must agree to use one of the contraception methods.\n* No history of diabetes.\n\nExclusion Criteria:\n\n* Clinically meaningful abnormalities in routine bloods including:\n\n  * eGFR \\\u003C 60ml\u002Fmin\n  * Elevation of liver enzymes\u002Fbilirubin\n  * Prolonged prothrombin time\n  * Thrombocytopenia\n* Use of the following medications or therapies:\n\n  * P450 CY3A4 inhibitors\n\n    * Potent: Boceprevir, Clarithromycin, Cobicistat, Idelalisib, Itraconazole, Ketoconazole, Nelfinavir, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazoleb\n    * Moderate: Aprepitant, Conivaptan, Crizotinib, Diltiazem, Dronedarone, Erythromycin, Fluconazole, Imatinib, Isavuconazole, Nefazodone, Netupitant, Nilotinib, Posaconazolee, Tofisopam, Verapamil\n    * Unclassified: Delavirdine\n  * P450 CY3A4 inducers\n\n    * Potent: Carbamazepine, Enzalutamide, Fosphenytoin, Mitotane, Phenytoin, Rifampicin\n    * Moderate; Bosentan, Efavirenz, St John's wort\n    * Unclassified; Barbiturates, Nevirapine, Primidone, Rifabutin, Rifapentine\n  * oral contraceptives\n  * oral anticoagulants or antiplatelet agents other than low dose aspirin\n  * levothyroxine\n* Currently breastfeeding.\n* Any clinical significant medical conditions that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures.\n* History of any clinical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study, such as some chronic systemic diseases affecting blood, liver or kidneys or endocrine system.\n* Unwillingness or inability to follow the procedures outlined in the protocol.\n* Subject is mentally or legally incapacitated.\n* Contraindication to XBD173 use:\n\n  * Hypersensitivity to the active substance or to any of the excipients",true,"ALL","18 Years","75 Years",{"count":23,"type":24},50,"ESTIMATED","INTERVENTIONAL",[27],"PHASE2","The goal of this clinical trial is to learn whether a single dose of XBD173, a medicine that binds to a protein called the 18 kiloDalton Translocator Protein (TSPO), affects how the body processes glucose in healthy volunteers aged 18 to 75 years.\n\nThe main questions it aims to answer are:\n\n* Does a single dose of XBD173 change fasting blood glucose levels compared with placebo?\n* Does a single dose of XBD173 change blood glucose levels after participants drink a glucose solution compared with placebo?\n\nResearchers will compare XBD173 with a placebo, which does not contain the active medicine, to see whether activating TSPO affects glucose metabolism in the fasting state and after a glucose drink.\n\nParticipants will:\n\n* Attend a screening visit to confirm eligibility, including a medical history, physical examination and blood tests.\n* Attend four study visits after fasting overnight: two visits involving a glucose drink and two visits without a glucose drink.\n* Receive a single oral dose of XBD173 at some visits and placebo at other visits. The order will be randomised, and neither participants nor the study team conducting the assessments will know which treatment is given during each visit.\n* Have repeated blood samples taken through a cannula to measure glucose, insulin and other markers related to metabolism and inflammation.\n* Have resting energy use measured by breathing under a transparent canopy connected to a standard metabolic measurement device.\n* Have blood pressure, heart rate, height and weight measured.\n* Undergo measurement of blood vessel function using a cuff.",[30],"Heathly Volunteers",[32,33,34,35,36,37,38,39,40,41,42,43,44,45],"TSPO","18 kDa Translocator Protein","XBD173","Glucose Metabolism","Fasting Plasma Glucose","Oral Glucose Tolerance Test","OGTT","Insulin Response","Resting Energy Expenditure","Respiratory Quotient","Healthy Volunteers","Randomised Controlled Trials","Randomised Crossover Study","Placebo-Controlled Trial","RECRUITING","2026-06-26",{"date":49,"type":50},"2026-07-02","ACTUAL",{"date":52,"type":50},"2026-03-27",{"date":54,"type":24},"2028-09-01",{"name":56,"class":57},"Imperial College London","OTHER",1,{"id":60,"slug":61,"hasResults":12,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":66,"targetDuration":68,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":23},"100642865","the-uk-22-week-study-100642865","NCT07616778","The UK 22 Week Study","Clinical Management and Short-Term Outcomes of Neonates Born at 22 Weeks in the UK (The 22 Week Study)","Inclusion Criteria:\n\n* Born at 22+0-22+6 weeks gestational age\n* Born in a NICU centre with neonatal team in attendance\n* Or admitted to a NICU within first 72 hours of life if outborn\n\nExclusion Criteria:\n\n* Less than or more than 22 weeks gestation at birth\n* Known congenital anomaly",{"count":67,"type":24},100,"6 Months","OBSERVATIONAL","In the UK, babies born at 22 weeks of pregnancy have only been offered survival-focused care (sometimes called resuscitation or stabilisation) since 2019. Very few babies are born this early each year and sadly a lot of them do not survive. Therefore, healthcare teams don't have much information about this new population of tiny babies and there is much to learn about how they respond, the problems they face and the best way for intensive care units to look after them.\n\nThis study aims to collect information available in babies' medical notes, analyse it and share learning to start improving this knowledge. There will be no changes to the babies' care, only observation of what happens.\n\nA small team of doctors and nurse practitioners who have\u002Fare looking after a baby, will put a small amount of selected information, without 'identifiers' such as the baby's name, date of birth or hospital number, onto a secure database platform at Imperial College London (a university).\n\nResearchers will analyse the information from all the babies around the UK together to look for trends and to describe common things that happen to them, as well as their outcomes.\n\nParents will be made aware this information is being collected and used through a leaflet. It will not be possible to identify an individual baby in the results.\n\nThe investigators are aiming for around 45 hospitals across the UK to participate. Babies born at 22 weeks gestation, who are attended to at birth by a neonatal team (or admitted) at an intensive care site over a 12-month period will be included. While collecting this information will not impact the babies included, it may help the treatment of babies born early in the future and give families more accurate information about what they might expect to happen.",[72,73,74,75],"Extreme Prematurity - Less Than 28 Weeks","Infant, Extremely Premature","Neonatal and Perinatal Conditions","Intensive Care, Neonatal",[77,78,79],"Neonatal","extreme prematurity","observational","2026-06-23",{"date":82,"type":50},"2026-06-24",{"date":84,"type":50},"2025-06-01",{"date":86,"type":24},"2027-12",{"name":56,"class":57},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":25,"phases":97,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100622653","study-of-lesion-specific-invasive-haemodynamic-angina-thresholds-100622653","NCT07386418","Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds","ORBITA-SOLAR","Inclusion Criteria:\n\n1. Eligibility for PCI due to angina or angina-equivalent symptoms on exertion\n2. 2 severe epicardial stenoses in a major coronary artery, defined as:\n\n   1. ≥70% stenosis in a coronary artery with ≥2.5mm diameter, on invasive coronary angiography (ICA)\n   2. Severe stenosis in a vessel with ≥2.5mm diameter, on CTCA\n3. Evidence of ischaemia on an invasive or non-invasive test, including:\n\n   1. Physiological test during invasive coronary angiography (ICA)\n   2. Dobutamine stress echocardiography (DSE)\n   3. Stress perfusion cardiac magnetic resonance (CMR)\n   4. Myocardial perfusion scintigraphy (MPS)\n   5. Fractional flow reserve computed-tomography (FFR-CT)\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Acute coronary syndrome within 3 months\n3. Previous coronary artery bypass graft\n4. Significant left main stem disease\n5. Single lesion amenable to PCI\n6. Chronic total occlusion of the target artery\n7. Moderate to severe valve disease\n8. LVEF ≤40%, contraindication to PCI or drug-eluting stents\n9. PCI performed with drug-eluting balloons without stenting\n10. Contraindication to antiplatelet therapy\n11. Contraindication to adenosine\n12. Physical inability to exercise with an ergometer\n13. Femoral artery access\n14. Pregnancy\n15. Inability to consent",{"count":96,"type":24},60,[98],"NA","ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds. The angina threshold is defined as the amount of coronary flow reduction required to reproduce symptoms. Sixty patients with symptoms of stable angina and 2 coronary artery stenoses amenable to percutaneous coronary intervention (PCI) will be recruited. This study will use intra-coronary balloon inflation during supine exercise on an ergometer to measure the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) that relates to angina onset, in real time, at the location of each stenosis.",[101,102,103],"Angina (Stable)","Coronary Artery Disease(CAD)","Ischaemic Heart Disease (IHD)",[105,106,107,108,109],"Angina","Coronary physiology","Coronary haemodynamics","Placebo-control","Symptoms",{"date":47,"type":50},{"date":112,"type":50},"2026-02-10",{"date":114,"type":24},"2028-12",{"name":56,"class":57},7,{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":25,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100520123","physiological-versus-right-ventricular-outcome-trial-evaluated-for-bradycardia-treatment-upgrades-100520123","NCT06052475","Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades","PROTECT-UP","Patients with an RV pacemaker and LVEF 35-50% and a high burden of right ventricular pacing (\\>40%) who are clinically indicated for a cardiac resynchronisation therapy upgrade procedure and:\n\n1. EF reduced by \\>5% of increase in LVESV by 10ml since implant\n2. NT-proBNP \\>250ng\u002FL in sinus rhythm\n3. NT-proBNP \\> 750 Ng\u002FL if AF\n4. Left atrial volume index \\> 30ml\u002Fm2\n5. Regular loop diuretics prescribed\n6. Decline in daily patient activity by \\>1 hour per day since implant\n7. Decrease in device measured thoracic impedance\n8. Patient reported decline in functional class or exercise tolerance\n\nExclusion Criteria:\n\n* Those unable to provide informed consent\n* Patients under age 18\n* Pregnant women",{"count":125,"type":24},155,[98],"Guidelines for patients having first-time implants advocate that even when heart function is only mildly impaired, modern pacing approaches should be utilised to avoid the potentially damaging effects of RV pacing to preventing symptoms from pacing induced or worsened cardiomyopathy.\n\nHowever, once a traditional (RV) pacemaker is implanted, development of impaired heart function does not prompt a device upgrade. Even at the end of battery life, physicians simply replace it like-for-like.\n\nThis trial tests whether such patients have better symptoms and quality of life if changed to a modern physiological pacing strategy from the traditional RV pacing approach.\n\nIn this crossover trial, participants will be upgraded to a physiological pacing strategy.\n\nAfter their procedure, they will have a one-month run-in period to recover from the procedure (their pacemaker will be programmed to continued RV pacing).\n\nThey will be have 2 one-month blinded time periods, randomised to physiological pacing or right ventricular pacing alternately. They will subsequently undergo two six-month blinded randomised time periods.\n\nPatients will document symptoms monthly on a mobile phone application or computer. At the end of each time period, they will have measurements of heart function, a walking test and quality-of-life questionnaires including the SF-36 questionnaire.\n\nThe investigators hypothesise that upgrading to physiological pacing strategies will improve patients' quality of life.",[129,130],"Pacing-Induced Cardiomyopathy","Heart Failure",[132,133,134,135],"Physiological Pacing","RV Pacing","Biventricular Pacing","Pacemaker Upgrade","2026-06-22",{"date":80,"type":50},{"date":139,"type":50},"2023-09-04",{"date":141,"type":24},"2027-09-04",{"name":56,"class":57},12,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":151,"targetDuration":4,"studyType":25,"phases":153,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":58},"100643847","3d-reconstruction-vr-and-machine-learning-in-body-image-in-bariatrics-100643847","NCT07668492","3D Reconstruction, VR and Machine Learning in Body Image in Bariatrics","The Use of 3D Reconstruction, Virtual Reality, and Machine Learning in Addressing Body Image in Bariatric Metabolic Surgery.","Inclusion Criteria:\n\n* Tier 4 bariatric group\n* On waiting list for bariatric metabolic surgery\n* Able to stand unaided for at least 5 minutes\n\nExclusion Criteria:\n\n* Anyone who cannot provide informed consent\n* Anyone who is involved in current research or has recently been involved in any research prior to recruitment.",{"count":152,"type":24},80,[98],"Studies have shown that following bariatric metabolic surgery (BMS), patients continue to experience dissatisfaction with their new body image and identity). The reason for this is poorly understood but negative body image perception after surgery is linked to poor psychological and clinical outcomes. Our pilot study looking at the acceptability and feasibility of 3D reconstruction and virtual reality (VR) in addressing body image in BMS found that participants felt better informed about how their body will change following significant weight loss and agreed this novel intervention would be beneficial in helping patients adjust to changes in their body after BMS.\n\nThe investigators propose a randomised control trial comparing group body image counselling and group body image counselling with 3D reconstruction and VR in addressing body image in BMS. The study aims to enrol 80 participants from the Tier 4 bariatric group at St Mary's Hospital and Chelsea \\& Westminster Hospital. After consent, participants will be divided into two groups: the control group will receive traditional group body image counselling, and the intervention group will receive the same counselling supplemented with VR and 3D reconstructed images depicting 15% and 25% total less body weight. Both groups will undergo four sessions over six months.\n\nThe investigators will collect data including body measurements and 3D images of the participant in their underwear using a secure password protected device at baseline and follow participants at 3, 6, 9, 12, 18, 24, and 36 months post-BMS. Patient reported outcomes will be assessed through patient-reported questionnaires.\n\nThis trial seeks to determine if integrating 3D reconstruction and VR technology into body image counselling can provide better support for patients adjusting to body image changes post-BMS, potentially leading to improved psychological and clinical outcomes.",[156,157,158,159],"Obesity (Disorder)","Body Image","Mental Health","Bariatric Surgery",[161,162,157,163,164],"3D Reconstruction","Virtual Reality","Machine Learning","Bariatric Metabolic Surgery","NOT_YET_RECRUITING","2026-06-19",{"date":168,"type":50},"2026-06-25",{"date":170,"type":24},"2026-06",{"date":172,"type":24},"2030-03",{"name":56,"class":57},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100641375","an-observational-study-into-antimicrobial-resistance-in-patients-with-a-chronic-lung-disease-100641375","NCT07646691","An Observational Study Into Antimicrobial Resistance in Patients With a Chronic Lung Disease","Prospective Study of Antimicrobial RESIstance in Chronic Lung DiseasE","PRESIDE","Inclusion Criteria:\n\n* Presence of an underlying chronic lung disease (e.g. Bronchiectasis, COPD) stratified by colonisation status:\n\n  * Pseudomonas sp (n=30)\n  * Klebsiella sp (n=20)\n  * Haemophilus sp (n=20)\n  * E-coli sp (n=20)\n  * Stenotrophomonas sp (n=20)\n  * Staphylococcus sp (n=20)\n  * Other chronic colonisation (n=20)\n  * Not colonised with any bacterial pathogen (n=20)\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Pregnancy\n* Medical instability preventing ability to attend for regular study visits at baseline.",{"count":183,"type":24},170,"Antimicrobial resistance (AMR) refers to the ability of microorganisms like bacteria, viruses, fungi and parasites to resist the effects of antimicrobial drugs (such as antibiotics) which are widely used as treatment. AMR poses an escalating global health threat, contributing to difficult-to-treat infections associated with increased disease spread, disability and death, as well as a substantial economic burden.\n\nIn chronic lung diseases, such as bronchiectasis, Cystic fibrosis or chronic obstructive lung disease (COPD), there is a higher risk of AMR due to the exposure to frequent or prolonged courses of antibiotics to treat recurrent lung infections and exacerbations (flares of the disease), to reduce lung inflammation or to control chronic infection within the lung with suppression of colonising microbes.\n\nMost data on AMR in chronic lung diseases derive from analysing pre-existing routinely collected health data collected on a national basis which is often incomplete. Hence a prospective study is crucial to better understand and address AMR in chronic lung diseases. Prospective studies follow patients forward in time, collecting data on outcomes and allowing researcher to observe the natural history of AMR development, monitor trends and evaluate interventions.\n\nThis multicentre prospective study, as part of the European Respiratory Society (ERS) Clinical Research Collaboration on Antimicrobial Resistance in Lung Disease (CRC - AMR Lung), aims to investigate the patterns of AMR in chronic lung diseases through a fully anonymous registry alongside a prospective sub-cohort study tracking individuals with chronic lung disease and known colonisation with high-priority AMR pathogens (microorganisms). This study will enable analysis of prevalence and burden of AMR within chronic lung disease alongside understand the genetic drivers of resistance, the link between the microbial genotype and antimicrobial resistance and how transmission of resistance occurs in chronic lung disease.",[186],"Chronic Lung Diseases",[188,189],"antimicrobial resistance","chronic lung disease","2026-06-17",{"date":136,"type":50},{"date":193,"type":24},"2026-07-01",{"date":195,"type":24},"2028-12-01",{"name":56,"class":57},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":25,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":228},"100644401","tackling-resistance-and-healthcare-economics-through-cpe-screening-100644401","NCT07663110","Tackling Resistance And HealthCare Economics Through CPE Screening","Multi-centre Evaluation of Carbapenemase-producing Enterobacterales (CPE) Prevalence and Transmission Dynamics, Recommendations on Screening Strategies, and Health Economics Outcomes Research Impact to Inform Policy Change","TRACE-CPE","Inclusion Criteria:\n\n* All adult (18 years or older) medical patients admitted to the acute medical unit during the implementation period who undergo routine rectal CPE testing as per local Trust policy and test positive for CPE colonisation through either the rapid test or culture-based methods.\n\nExclusion Criteria:\n\n* Patient refusal for rectal screening or\n* Clinical contraindication to rectal swab collection",{"count":206,"type":24},16000,[98],"The goal of this clinical study is to learn if it is possible to reduce the spread of resistant bacteria called CPEs (Carbapenemase producing Enterobacterales) between patients admitted to hospital.\n\nCPEs can be carried in the gut of people without making them ill. Normally when patients come into hospital, they may undergo a swab test on their bottom to see if CPEs can be grown. This test can take up to 24 hours to produce a result.\n\nThe investigators want to use a faster test which takes 2 hours to produce a result, and whether this can make a difference to CPE spread between person to person.\n\nThe main questions it aims to answer are:\n\n1. Why do people carry, transmit or get infected with CPE?\n2. If a faster test was used to look for CPE, would this be better at reducing patient spread in hospital?\n3. Is a faster test also more cost effective?\n\nParticipants will:\n\n1. Be tested by both the usual and faster test when they come into hospital by a swab on their bottom\n2. Where they test positive for CPE they will be asked to answer some questions about their health",[210,211],"Carbapenem-Resistant Enterobacteriaceae","Colonisation",[213,214,215,216,217,218,219,220],"infection prevention and control","health economics","rapid molecular diagnostics","carbapenem-resistant Enterobacterales","CPEs","CROs","MDROs","hospital transmission","2026-06-16",{"date":80,"type":50},{"date":224,"type":24},"2026-08-01",{"date":226,"type":24},"2028-03-31",{"name":56,"class":57},2,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":25,"phases":239,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":58},"100495779","phase-4-thromboprophylaxis-in-individuals-undergoing-superficial-endovenous-treatment-thrive-100495779","NCT05735639","THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial","THRIVE","Inclusion Criteria:\n\n* Adults (\\>18 years)\n* Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia\n* Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue\n\nExclusion Criteria:\n\n* Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation\n* Previous personal or first-degree relative history of VTE\n* Thrombophilia\n* Female patients of childbearing potential who have a positive pregnancy test\n* A history of allergy to heparins or direct oral anticoagulants\n* A history of heparin-induced thrombocytopenia\n* Inherited and acquired bleeding disorders\n* Evidence of active bleeding\n* Concomitant major health problems such as active cancer and chronic renal and\u002For liver impairment\n* Known thrombocytopenia (platelets known to be less than 50 x 109\n\n  \u002Fl)\n* Surgery or major trauma in the previous 90 days\n* Recent ischemic stroke in the previous 90 days\n* Inability to provide consent",{"count":238,"type":24},3175,[240],"PHASE4","Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.\n\nVaricose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.\n\nThis study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.",[243,244],"Venous Thromboembolism","Varicose Veins","2026-06-03",{"date":247,"type":50},"2026-06-04",{"date":249,"type":50},"2024-01-22",{"date":251,"type":24},"2027-12-31",{"name":56,"class":57},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":25,"phases":262,"briefSummary":263,"conditions":264,"keywords":268,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":278},"100639991","long-axial-field-of-view-lafov-18ffdg-petct-imaging-in-large-vessel-vasculitis-lvv-protocol-optimisation-study-100639991","NCT07628075","Long-Axial Field of View (LAFOV) [18F]FDG PET\u002FCT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.","LAVA-FLOW","Inclusion Criteria LVV Patients:\n\n* ≥18 years of age\n* Newly diagnosed LVV (based on the 2022 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria or from a definite diagnosis of LVV on standard of care imaging)\n* WHO performance status 0-2\n* The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained\n* eGFR of ≥30 (mL\u002Fmin\u002F1.73m2) within 3 months of \\[18F\\]FDG injection in subjects who have a history of renal impairment, renal disease, renal transplant or diabetes\n\nExclusion Criteria LVV Patients:\n\n* The subject is pregnant or lactating\n* Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure\n* History of allergy to iodinated contrast\n* Commencement of steroids \\> 7 days prior to administration of the radiotracer\n* Poorly controlled diabetic with a blood glucose \\>11mmol\u002FL\n* Evidence of a significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial.\n\nInclusion Criteria Healthy Volunteers:\n\n* Three subjects ≥18 years of age that are also \\\u003C 50 years old and three subjects ≥50 years of age\n* WHO performance status 0-2\n* The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained\n\nExclusion Criteria Healthy Volunteers:\n\n* The subject is pregnant or lactating\n* Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure\n* Participants with any contra-indication to MRI\n* Known allergy to gadolinium-based contrast agents\n* History of smoking\n* History or current diagnosis of the following medical conditions:\n* Diabetes Mellitus\n* Chronic Kidney Disease\n* Atrial Fibrillation\n* Migraines\n* Rheumatoid Arthritis\n* Systemic Lupus Erythematosus (SLE)\n* Historic or current prescription of the following medications:\n* Any blood pressure medication\n* Any antipsychotic medication\n* Steroids\n* Weight of ≥75Kg (in order to keep the radiation dose \\\u003C10mSV for HV)\n* Evidence of any significant medical condition which, in the opinion of the Investigator, makes it undesirable for the HV to participate in the trial\n* Participants that have undergone any imaging investigation that exposes them to radiation within the previous 12 months",{"count":261,"type":24},18,[98],"Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are unclear, and the diagnostic criteria currently used are varied. Accurate diagnosis is essential because it helps to tailor the treatment to each patient. Some treatments, such as steroids and immunosuppressive medications, can have significant side effects, so they need to be used carefully and only when truly needed.\n\nAn \\[18F\\]FDG Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) involves the injection of a small amount of radiolabelled sugar, which assesses glucose metabolism within the body. \\[18F\\]FDG PET\u002FCT is already used by the NHS to detect inflammation within the vessel walls and diagnose LVV. Current diagnostic criteria for LVV largely rely on visual assessment by a radiologist. This approach therefore has limitations and may not fully capture changes in the levels of inflammation over time.\n\nA new generation of scanners, known as Long Axial Field-of-View (LAFOV)-PET\u002FCT or Total Body PET, are currently transforming what is possible in the field of medical imaging. These LAFOV-PET\u002FCT scanners have new digital detectors that are more sensitive, produce sharper images, and can scan the entire body rapidly. This offers several potential advantages for patients with LVV, including the clearer detection of vessel wall inflammation, the ability to administer lower doses of the radiolabelled sugar (\\[18F\\]FDG), and the ability to take repeated pictures over time to measure subtle changes in blood flow and inflammation. Patients receiving a routine NHS \\[18F\\]FDG PET\u002FCT scan for LVV are typically scanned 60 minutes after injection of the radiotracer using a standard PET\u002FCT. Another benefit of LAFOV-PET\u002FCT scanners is their ability to assess the amount of the radiolabelled sugar taken up by the whole body almost as soon as it is injected which could give important additional information.\n\nAs part of the LAVA-FLOW study we are planning to combine LAFOV-PET\u002FCT with a CT Angiogram (CTA) in patients with LVV. A CTA is a scan that shows doctors what your blood vessels look like. It involves the injection of a dye into a vein that makes your blood vessels visible, highlighting vessel wall inflammation and vessel wall narrowing. This combination of LAFOV-PET\u002FCT and CTA therefore has the potential to give a much more detailed picture of LVV than is achievable using current methods.\n\nThe LAVA-FLOW study therefore aims to develop a standardised protocol to be used in different hospital centres across the UK for the imaging of LVV using LAFOV-PET\u002FCT. We also hope that the results of this particular study could lead to further larger studies with the potential to update the diagnostic criteria and improve the monitoring of this condition.",[265,266,267],"Large Vessel Vasculitis","Takayasu Arteritis","Giant Cell Arteritis (GCA)",[265,269,270,271],"[18F]FDG Long-Axial Field of View (LAFOV)-PET\u002FCT","Angiography","Protocol Optimisation","2026-06-01",{"date":247,"type":50},{"date":193,"type":24},{"date":276,"type":24},"2028-01-01",{"name":56,"class":57},3,{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":4},"100639601","womens-knowledge-about-induction-of-labour-and-its-association-with-their-experience-100639601","NCT07616765","Women's Knowledge About Induction of Labour and Its Association With Their Experience","Induction of Labour: Women's Knowledge and Experience","INFORM","Inclusion Criteria:\n\nWomen:\n\n* All pregnant women who are booked for IOL at Chelsea and Westminster Hospital NHS Foundation Trust which includes both Chelsea and Westminster Hospital and West Middlesex Hospital.\n* The ability to understand and sign a written informed consent form.\n* Singleton pregnancy.\n\nClinicians:\n\n• Working at Chelsea and Westminster Hospital NHS Foundation Trust which includes both Chelsea and Westminster Hospital and West Middlesex Hospital.\n\nExclusion Criteria:\n\nWomen:\n\n* Under age 18\n* Women who do not have sufficient understanding of the English language to provide informed consent or to complete the questionnaires and interviews independently\n* Those not meeting the inclusion criteria\n\nClinicians:\n\n• Those not meeting the inclusion criteria",{"count":288,"type":24},112,"Induction of labour (IOL) is a common procedure to initiate childbirth, around one in three pregnant women having their labour induced in the UK. Labour may be induced for many different reasons, including going past the due date, having high blood pressure, diabetes, concerns about the baby's growth, or reduced movements.\n\nIOL can be a complex and lengthy process, sometimes lasting up to seven days. Many women find that their expectations of IOL do not match their real experiences. Research shows that between 5% and 20% of women report a negative birth experience, and this can have lasting effects. These may include difficulties bonding with their baby, depression after birth, fear of future childbirth, or choosing a caesarean section next time.\n\nStudies also show that women who feel unprepared for induction, or who do not fully understand the benefits, risks, and steps involved, are more likely to have a difficult experience. At the same time, research suggests that some healthcare professionals may not feel fully confident in their knowledge of induction, and their decisions may be influenced by colleagues or local practice rather than evidence alone.\n\nThis project aims to understand how much women know about induction before it begins, how this knowledge affects their experience, and how well clinicians understand and communicate about induction.\n\nTo do this, investigators will invite women who are booked for induction at Chelsea and Westminster Hospital or West Middlesex Hospital to take part in two surveys: one before induction and one after birth. Women will also be able to volunteer for an interview to talk in more detail about their experience. They will also invite all maternity staff at the Trust to complete a short survey about their knowledge and attitudes towards induction, followed by optional interviews.\n\nInvestigators aim to recruit approximately 82 pregnant women and 20 to 30 clinicians (including midwives, obstetricians, and trainees) working in the maternity department at Chelsea and Westminster Hospital NHS Foundation Trust.",[291],"Induction of Labour",[293,294,295,296,297,298,299,300],"Induction of labour","Patient satisfaction","Pregnancy","Clinicians","Attitude","Maternity care","Women's Knowledge","Labour Induction","2026-05-27",{"date":272,"type":50},{"date":304,"type":24},"2026-05-01",{"date":306,"type":24},"2028-05-01",{"name":56,"class":57},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":316,"conditions":317,"keywords":320,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":58},"100611644","volatile-organic-compound-assessment-in-pancreatic-ductal-adenocarcinoma-vapor2-100611644","NCT07243262","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)","Inclusion Criteria:\n\n* Adult participants ≥ 18 years old\n* Referral from primary care according to the urgent suspected cancer referral guidelines for potential underlying pancreatic cancer, or referral directly to a pancreatic cancer multidisciplinary team meeting\n\nExclusion Criteria:\n\n* Previous pancreatic resection\n* History of another cancer (other than non-melanoma skin cancers) within three years\n* Pregnant participants (pregnancy status to be confirmed verbally with the participant)\n* Participants with co-morbidities preventing breath collection\n* Unable or unwilling to provide informed consent",{"count":315,"type":24},6079,"The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers.\n\nPancreatic cancer is a rare disease but patients are often diagnosed at a late stage because their symptoms are the same as those of many common illnesses. This makes it hard for doctors to know which patients need to be tested for pancreatic cancer. If the investigators find pancreatic cancer at a late stage, it reduces the number of treatment choices for patients.\n\nOur test could be offered to patients who are experiencing vague symptoms, which might be caused either by pancreatic cancer or a common illness. This test could help doctors to identify which of those patients may have pancreatic cancer, and ensure they get referred for specialised pancreatic cancer tests. The investigators hope that this will allow us to diagnose pancreatic cancer earlier, increasing treatment choices for patients and improving survival from pancreatic cancer.\n\nThe investigators have previously conducted a study (VAPOR1) which collected breath samples from people with and without pancreatic cancer. When the investigators analysed these samples, they found that there is a difference in the volatile organic compounds breathed out by people who have pancreatic cancer compared to those that do not. The investigators used these 'markers' to develop a breath test to diagnose pancreatic cancer. In VAPOR2, the investigators will study our breath test in a much larger group of patients who have been referred for further investigations for potential underlying pancreatic cancer to see how accurately it can pick up the small percentage of people who have pancreatic cancer.",[318,319],"Pancreatic Cancer","PDAC - Pancreatic Ductal Adenocarcinoma",[321,322,323,324,325],"Volatile organic compounds (VOCs)","Breath analysis","Volatolomics","Validation","Early detection of cancer","2026-05-15",{"date":328,"type":50},"2026-05-19",{"date":330,"type":50},"2025-10-21",{"date":332,"type":24},"2028-08-01",{"name":56,"class":57},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":58},"100495118","volatile-organic-compound-assessment-in-pancreatic-ductal-adenocarcinoma-100495118","NCT05727020","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR 1 \u002F BIORESOURCE)","VAPOR","Inclusion Criteria:\n\n* Males and females\n* Adult patients ≥ 18 years old\n* VAPOR 1: patients with either a) Histologically confirmed PDAC\\*; b) New-onset diabetes mellitus or chronic pancreatitis; or c) Non-specific gastrointestinal symptoms, but a radiologically-normal pancreas\n* VAPOR Bioresource: patients undergoing pancreatic resection for a) Histologically confirmed PDAC\\*; or b) Benign pancreatic disorders e.g. intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis\n\nNote: \\*Patients undergoing surgery for suspected PDAC (without pre-operative histological confirmation) may be recruited assuming PDAC is confirmed within the resected specimen.\n\nExclusion Criteria:\n\n* Patients who have already received chemotherapy, radiotherapy or surgery for their PDAC\n* History of another cancer within the previous five years\n* Previous upper gastrointestinal surgery\n* Patients who are unable to provide a breath sample\n* Pregnant women\n* Patients unable to provide informed written consent\n* VAPOR 1: Patients with active infection, receiving immunosuppressive medications or antibiotics within the preceding eight weeks\n* VAPOR Bioresource: Patients receiving immunosuppressive medications within the preceding eight weeks",{"count":343,"type":24},1005,"Patients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all. Jaundice, weight loss and pain are 'red flag' symptoms of pancreatic cancer that are linked to incurable disease. At the moment only patients with 'red flag' symptoms are urgently referred for diagnostic testing to find out if they have the cancer. As a result, late diagnosis is a common feature of pancreatic cancer. This leads to limited treatment options being available to patients by the time they are diagnosed, and ultimately results in poor survival rates.\n\nThere is a clear need to improve earlier detection of pancreatic cancer so that patients with pancreatic cancer can be identified earlier and faster, enabling them to start treatment more quickly.\n\nThe study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that may be altered by pancreatic cancers. For patients with non-specific symptoms, this test would help general practitioners (GPs) to identify those patients that may indeed have an underlying pancreatic cancer, who would benefit from referral for specialised pancreatic cancer tests.",[319,318],[321,322,323,347,348,349,350,351],"Metabonomics \u002F Lipidomics","Transcriptomics","Microbiome Analysis","Organoids","Immune profiling",{"date":353,"type":50},"2026-05-18",{"date":355,"type":50},"2022-12-15",{"date":357,"type":24},"2028-08",{"name":56,"class":57},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":25,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":376,"leadSponsor":378,"locationsCount":58},"100520842","artificial-intelligence-delivered-cardiac-magnetic-resonance---prospective-validation-100520842","NCT06061822","Artificial Intelligence Delivered Cardiac Magnetic Resonance - Prospective Validation","AID-MR","Inclusion Criteria:\n\n* Adult (aged at least 18 years)\n\nExclusion Criteria:\n\n* Children (patients below age 18).\n* Pregnant patients.",{"count":367,"type":24},150,[98],"Cardiac MRI (CMR) scanning allows doctors to create detailed images of the heart. However, the need for experienced cardiac radiographers to perform each scan can make CMR's delivery difficult, and some patients in the UK wait more than half a year for a scan. These radiographers must take pictures of different part of the heart, termed \"views\", each of which must be precisely positioned.\n\nThe investigators believe they can revolutionise CMR, by using artificial intelligence to automatically position the views so radiographers can focus on more difficult tasks.\n\nThe investigators have used a retrospective database of pseudonymised (anonymised and linked) CMR scans at our hospital to create these artificial intelligence (AI) algorithms, and they have validated them retrospectively on previous studies. The investigators now wish to test the algorithms prospectively.\n\nIn this study, the investigators will recruit patients undergoing clinical CMR scans. In addition to the routine images acquired by expert radiographers, the investigators will require a duplicate set of images, positioned and planned by the AI algorithms.\n\nThe investigators will then compare, within each patient, the AI-planned and expert-radiographer-planned scanning in terms of both speed and image quality.",[371,42],"Cardiovascular Diseases","2026-05-06",{"date":374,"type":50},"2026-05-11",{"date":304,"type":50},{"date":377,"type":24},"2027-12-01",{"name":56,"class":57},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":25,"phases":387,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":58},"100635677","motivating-core-muscle-exercises-with-wearable-sensors-haptics-and-interactive-gaming-100635677","NCT07555795","Motivating Core-muscle Exercises With Wearable Sensors, Haptics and Interactive Gaming","Inclusion Criteria:\n\n1. Over the age of 18\n2. Non-specific LBP for at least 6 weeks in the past 12 months\n3. Pain 4\u002F10 on a visual analogue scale or more or Oswestry Disability Index over 20%\n\nExclusion Criteria:\n\n1. Serious spinal pathology (\"red flags\") such as:\n\n   * History of malignancy with new onset back pain suggestive of recurrence.\n   * Unexplained weight loss, fever, or systemic symptoms.\n   * Recent significant trauma (e.g., fall from height, road traffic accident).\n   * Suspected or confirmed spinal infection (e.g., discitis, osteomyelitis).\n   * Cauda equina symptoms, including urinary retention\u002Fincontinence or saddle anaesthesia.\n   * Progressive neurological deficit (e.g., worsening weakness, loss of reflexes).\n2. Recent spinal surgery or invasive spinal procedures within the past 3 months.\n3. Severe cardiovascular or respiratory disease that prevents safe participation in mild to moderate exercise (e.g., unstable angina, uncontrolled heart failure).\n4. Pregnant women or those less than three months postpartum.\n5. Known allergy to materials used in the belt (e.g., Lycra or related fabrics).\n6. Cognitive impairment that prevents informed consent or ability to follow exercise instructions.\n7. Concurrent participation in another intervention trial that may interfere with the study outcomes.",{"count":386,"type":24},40,[98],"The goal of this clinical trial is to evaluate whether a wearable biofeedback smartbelt system can improve pain and disability in adults with chronic lower back pain. The intervention combines a wearable belt that measures muscle activity with a mobile application that provides real-time feedback during exercise.\n\nThe main questions it aims to answer are:\n\n* Does the MMG-biofeedback system improve disability, as measured by the Oswestry Disability Index (ODI), compared to standard care alone over an 8-week period?\n* Does the system reduce perceived pain levels and improve exercise adherence in individuals with lower back pain over an 8-week period?\n\nResearchers will compare participants receiving the MMG-biofeedback belt alongside standard care to those receiving standard care alone to determine whether the addition of real-time muscle activation feedback leads to improved outcomes.\n\nParticipants will:\n\n* Be randomly assigned to either the intervention group (biofeedback system + standard care) or control group (standard care only)\n* Complete an 8-week home-based exercise programme, all participants are asked to complete the programme at least 5 times a week\n* Use the wearable belt and mobile application during exercise sessions (intervention group only)\n* Receive a booklet with the exercise programme and video links (control group only)\n* Complete questionnaires on pain, disability, and usability at baseline and after 8 weeks, and at a 3-month follow-up\n* Have their exercise adherence and engagement monitored throughout the study\n\nThe study includes an initial pilot phase to assess feasibility, followed by a larger randomised controlled phase to evaluate early clinical effectiveness.",[390,391],"Non-specific Low Back Pain","Low Back Pain",[393,394,395,396],"wearables","core muscle","exercise therapy","biofeedback","2026-04-21",{"date":399,"type":50},"2026-04-29",{"date":401,"type":50},"2026-04-20",{"date":403,"type":24},"2027-04-20",{"name":56,"class":57},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":25,"phases":416,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":58},"100563747","generating-mucosal-immunity-after-influenza-infection-and-vaccination-in-lung-and-lymphoid-tissue-100563747","NCT06620185","GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE","A Two-arm, Non-randomised, Open-label Experimental Medicine Study to Compare Immune Responses Between Healthy Volunteers Aged 18-55years Receiving Either an Intranasal Live-attenuated Influenza Vaccine or Viral Challenge With GMP Influenza A\u002FBelgium\u002F4217\u002F2015 (H3N2)","GERMINATE","Inclusion Criteria:\n\n* Adults aged between 18-55 years inclusive\n* Sero-suitable as defined by a serum micro-neutralisation titre \\\u003C1:20\n* Female participant who is not of child-bearing potential as assessed by an investigator OR is willing and able to use contraception as described in the protocol\n* Male participants who are willing to use one of the contraception methods described in the protocol\n* In good health with no clinically significant medical conditions\n\nExclusion Criteria\n\n* History of clinically significant\u002Fcurrently active conditions;\n\n  * Cardiovascular, thromboembolic\u002Fcerebrovascular disease.\n  * Types of chronic respiratory disease in adulthood.\n  * Significant wheeze in the past\n  * Respiratory symptoms including wheeze, resulting in hospitalisation\n  * Known bronchial hyperactivity to viruses\n  * Diabetes mellitus\n  * Migraine with associated symptoms like hemiplegia\u002Fvision loss. Cluster headache\u002Fmigraine\u002Fprophylactic treatment for migraine.\n  * History of autoimmune disease\u002Fknown immunodeficiency of any cause\n  * Immunosuppression.\n  * Known coagulation disorder\u002Fanticoagulant therapy\n  * Psychiatric illness including participants with a history of depression and\u002For anxiety with associated psychiatric comorbidities\n  * Other major disease that, under the PI's discretion, could interfere with the participant completing the study.\n* Concurrent serious illness including history of malignancy that could interfere with the study or a participant completing the study.\n* Known IgA deficiency\u002Fimmotile cilia syndrome\u002FKartagener's syndrome\n* Significant abnormality altering the anatomy\u002Ffunction of the nose or nasopharynx, a clinically significant history of epistaxis within the last 3 months, nasal\u002Fsinus surgery within 6 months of Day 0, including nasopharyngeal malignancy, arterio-venous malformation, or undiagnosed nasopharyngeal mass\n* Inhaled bronchodilator\u002Finhaled steroid use within the last 12 months before Day 0\n* Acute upper respiratory tract infection in the past 6 weeks.\n* Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months before Day 0\n* Receipt of any vaccine within 30 days of Day -14\n* Any significant medical condition\u002Fprescribed drug, under the PI's discretion\n* Presence of cold-like symptoms and\u002For fever on Day -14 or Day 0.\n* Receipt of blood\u002Fblood products\u002Floss (including blood donations) of 550 mL or more of blood during the 3 months prior to Day -14.\n* Significant history\u002Fpresence of drug\u002Falcohol misuse by self-report.\n* Current use of drugs through nose inhalation or inhaled route including recreational drugs.\n* Regular smoking and\u002For vaping and\u002For using nicotine-containing products in the past 3 months OR \\>5 pack-year lifetime history by self-report (5 pack years is equivalent to one pack of 20 cigarettes per day for 5 years).\n* History of anaphylaxis and\u002For a history of severe allergic reaction or significant intolerance to any food\u002Fdrug, as assessed by the PI.\n* Clinically active rhinitis (including hay fever)\u002Fhistory of moderate to severe rhinitis\u002Fhistory of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and\u002For requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of enrolment.\n* Anyone with any of the following contraindications to receiving the Fluenz Tetra Vaccine:\n\n  * Allergy to gentamicin, gelatin or the other ingredients of the fluenz vaccine.","55 Years",{"count":415,"type":24},36,[98],"This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.",[419],"Influenza",[421,422,423,419,424],"LAIV","Challenge","Vaccine","Flu","2026-04-15",{"date":401,"type":50},{"date":428,"type":50},"2025-04-16",{"date":430,"type":24},"2026-07-31",{"name":56,"class":57},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":440,"minAge":20,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":58},"100613246","identifying-the-best-follow-up-approach-for-people-who-have-had-treatment-to-cure-newly-diagnosed-prostate-cancer-100613246","NCT07264088","Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer","The FOLLOW UP Study - a Natural Experiment Estimating the Clinical and Cost-effectiveness of Follow up Strategies After Curative Treatment for Prostate Cancer","FOLLOW-UP","Inclusion criteria:\n\nAll hospitals in England that provide radical prostatectomy or radical radiotherapy or focal therapy for prostate cancer and are identified by clinicians as receiving one of the four follow up strategies of interest will be eligible for inclusion in the study.\n\nIndividual patients satisfying the following criteria will be eligible for inclusion:\n\n* Having newly-diagnosed non-metastatic, clinically localised prostate cancer (ICD-10 code C61) in the Cancer Registry between 1 January 2018 and 31 December 2023;\n* Age 18 or over at diagnosis;\n* Completed primary curative treatment at an eligible hospital between 1 January 2019 and 31 December 2023 with either: radical radiotherapy +\u002F- hormones, or radical prostatectomy with curative intent +\u002F- lymphadenectomy, or focal therapy, in keeping with local practice;\n* Alive with no disease progression or metastasis 6 months after the date of completion of primary curative treatment.\n\nExclusion criteria:\n\n* Men who are treated for metastatic cancer; or receiving palliative prostate cancer care;\n* Men who have opted out of their data being used as part of national routine data sets will be excluded (https:\u002F\u002Fdigital.nhs.uk\u002Fservices\u002Fnational-data-opt-out).\n\nRecruitment to the survey component of the study will be limited to a sub-cohort of eligible participants that additionally meet the following criteria:\n\n* Alive;\n* Have achieved between three to four and a half years of follow up (from completion of initial curative treatment) during the survey period.","MALE",{"count":442,"type":24},100000,"Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly. The organisation of these check-ups varies across the country as it is not known which approach is best. The four different established approaches are (i) check-ups performed in hospital outpatients by the same team that provided treatment; (ii) patients seen regularly by their GP with hospital referral as necessary; (iii) planned shared care between general practice and hospital follow up; or (iv) patients supported to provide checks on themselves (self-care) and reaching out to a doctor or a nurse when required. This study will compare these options to establish which is best for patients and makes the best use of the NHS resources.",[445],"Prostate Cancer",[447,448,449,450,451,452,453,454,455],"prostate cancer","prostate cancer after curative treatment","prostate cancer follow up","propensity-matched cohort study","qualitative","discrete choice experiment","economic evaluation","routine data","patient survey","2026-04-13",{"date":458,"type":50},"2026-04-16",{"date":460,"type":24},"2026-10",{"date":462,"type":24},"2027-07",{"name":56,"class":57},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":18,"sex":19,"minAge":472,"maxAge":21,"enrollmentInfo":473,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":474,"conditions":475,"keywords":479,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":58},"100601572","using-multiomics-to-define-mechanisms-of-rhinovirus-induced-chronic-obstructive-pulmonary-disease-exacerbations-to-develop-novel-therapies-and-therapeutic-targets-100601572","NCT07112235","Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","Using Multiomics to Define Mechanisms of RhinoVirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","MRVCOPD","Inclusion Criteria for COPD subjects\n\n* Male or female sex\n* Age ≥40 years and ≤75 years at the time of signing the consent form\n* Medical history or clinical diagnosis of COPD\n* Significant smoking history, defined as:\n\n  * Cumulative smoking history of at least 20 pack years\n  * Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n* COPD spirometry criteria:\n\n  * Post bronchodilator FEV1 of \\\u003C80% and ≥50% predicted for age and height (equivalent to GOLD criteria stage 2 for 'Moderate' severity COPD9)\n  * Post-bronchodilator FEV1\u002FFVC ratio \\\u003C0.7\n  * β-agonist reversibility: an improvement of less than 12% predicted FEV1 and less than 200mL after 200 micrograms of salbutamol or equivalent short acting beta-2 agonist bronchodilator.\n* History of acute exacerbations of COPD as defined by the participant answering \"yes\" to the question: \"do your COPD symptoms get noticeably worse when you catch a cold?\"\n* Clinically stable with no COPD exacerbations within 8 weeks prior to enrolment\n* Permitted to take short and long-acting bronchodilators including beta agonists and muscarinic antagonist inhalers\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active within 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than COPD, asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy\n\nInclusion Criteria for non-smoking controls\n\n* Male or female sex\n* Age ≥ 40 years and ≤ 75 years at the time of signing the consent form\n* No history or clinical diagnosis of COPD\n* No significant smoking history, defined as:\n\n  * Less than 5 pack year cumulative smoking history\n  * Has not smoked or used e-cigarettes\u002Fvapes in the last 1 year\n* Controls spirometry criteria\n\n  * FEV1 of ≥80% predicted for age and height\n  * FEV1\u002FFVC ratio ≥0.7\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active in the 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy.\n\nInclusion Criteria for smoking controls\n\n• Identical to non-smoking controls, with the exception of smoking history:\n\n* Cumulative smoking history of at least 20 pack years.\n* Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n\nExclusion Criteria:\n\n* Participants with other causes of chronic airflow limitation, including but not limited to:\n\n  * Bronchiectasis including cystic fibrosis\n  * Bronchiolitis obliterans\n  * Carcinoma of the bronchus\n  * Fibrosis such as tuberculosis (TB), idiopathic pulmonary fibrosis\n* Presence of any significant systemic disease, that in the opinion of the investigator would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured.\n\n  * For example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric conditions.\n* Pregnant, planning to become pregnant, testing positive for pregnancy at the screening visit test, or nursing females during and within 30 days of treatment.\n* Treatment with oral, inhaled or nasal corticosteroids within 8 weeks prior to enrolment.\n* Treatment with antibiotics in the 8 weeks preceding enrolment.\n* Treatment with nasal medications, anti-leukotrienes, anti-histamine at the time of the study.\n* Presence (at screening) of serum rhinovirus-A16 neutralising antibodies in a titre \\>1:2.\n* Individuals with close contact to at risk patient group, including:\n\n  * Infants (less than 6 months);\n  * The extremely elderly or infirm;\n  * Pregnant and\u002For breastfeeding women;\n  * Patients with immunosuppression (e.g., human immunodeficiency virus (HIV), transplant recipients on anti-rejection medications, those undergoing chemo- or immuno-therapy).\n  * Other factors that in the opinion of the investigator are considered a risk.\n* Participation in other clinical research studies that, in the opinion of the investigator, would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured in this or other studies, or (c) present an unacceptable visit burden to the participant.","40 Years",{"count":23,"type":24},"The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses.\n\nThe main questions the study aims to answer are:\n\n* What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations?\n* Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD?\n\nThe study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.",[476,477,478],"COPD (Chronic Obstructive Pulmonary Disease)","Rhinovirus Infection","Exacerbation of COPD",[480,481,482,483,484,485],"COPD","Chronic Obstructive Pulmonary Disease","Exacerbation","Multiomics","Rhinovirus","Viral challenge study",{"date":487,"type":50},"2026-04-14",{"date":489,"type":50},"2025-10-08",{"date":491,"type":24},"2027-03-31",{"name":56,"class":57},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":504,"conditions":505,"keywords":512,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":116},"100607733","health-related-quality-of-life-and-household-financial-and-wellbeing-impacts-of-prematurity-and-necrotising-enterocolitis-nec-100607733","NCT07192393","Health-Related Quality-of-Life and Household Financial and Wellbeing Impacts of Prematurity and Necrotising Enterocolitis (NEC).","Quantifying the Household Impact on Patient-Reported Outcomes and Costs Associated With the Care of Preterm Babies With and Without Necrotising Enterocolitis (NEC): A Study Alongside the Withholding Enteral Feeds Around Blood Transfusion (WHEAT) Trial","PREM-IMPACT","Inclusion Criteria:\n\n* Preterm birth \\\u003C30 gestational weeks\n\nExclusion Criteria:\n\n* Parent(s) of a preterm baby who died of necrotising enterocolitis (NEC)\n* Parent(s) unwilling or unable to provide written informed consent\n* Parent(s) and sibling(s) unable to understand English.","30 Weeks",{"count":503,"type":24},90,"PREM-IMPACT is a UK-based observational study exploring how caring for a very premature baby-particularly one affected by necrotising enterocolitis (NEC)-impacts families over the first year after hospital discharge. NEC is a serious bowel disease that can occur in premature babies, often requiring surgery and prolonged hospitalisation.\n\nThis study runs alongside the WHEAT International Trial, which investigates whether pausing or continuing milk feeds during blood transfusions affects the risk of NEC in very preterm babies. PREM-IMPACT acts as a nested economic evaluation of the WHEAT Trial, helping to understand whether different feeding practices around transfusion offer good value for money from both the NHS and family perspective.\n\nPREM-IMPACT will collect detailed data on babies' health-related quality of life, as well as the financial, emotional, and social impact on parents and siblings. Families are recruited from neonatal units when their baby is ready to go home and complete questionnaires at three timepoints: 1) just before discharge, 2) six months later, and 3) twelve months later. Questionnaires cover health, wellbeing, healthcare use, and costs to the family (such as travel, time off work, or extra care needs). A dedicated research nurse based at the lead NHS site helps coordinate follow-up centrally.\n\nBy studying families of babies with and without NEC, this project aims to clarify the burden of prematurity and NEC on infant outcomes and family wellbeing. The results will inform future policy decisions, including whether pausing or continuing milk feeds during transfusion should be adopted in routine neonatal care.",[506,507,508,509,510,511],"Prematurity; Extreme","Prematurity; Decision Support","Necrotising Enterocolitis","Preterm","Preterm Birth","Preterm Infant Health",[513,514,515,516,517,518,509,519,520,521],"NEC","Cost-Effectiveness Analysis","Cost-Utility Analysis","Health-Related Quality of Life","HR-QoL","Prematurity","Health Economic Analysis","Financial Impact","Wellbeing",{"date":523,"type":50},"2026-03-30",{"date":525,"type":50},"2025-08-08",{"date":527,"type":24},"2027-10-31",{"name":56,"class":57},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":440,"minAge":20,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":25,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":143},"100537665","imperial-prostate-9---atlas-approaches-to-long-term-active-surveillance-100537665","NCT06280781","Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)","A Randomised Controlled Trial of Regular MRI Scans Compared to Standard Care in Patients With Prostate Cancer Managed Using Active Surveillance","IP9-ATLAS","Inclusion Criteria:\n\n* Age 18 years or above (no upper limit)\n* Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone use at all).\n* Diagnostic bi-parametric or multiparametric MRI\n* Diagnostic systematic biopsy +\u002F- targeted biopsy\n* A histological diagnosis of localised prostate cancer\n* Patient chosen active surveillance\n\nExclusion Criteria:\n\n* On active surveillance for greater than 9 months prior to screening date.\n* Contraindication to MRI or gadolinium contrast\n* Previous hip replacement to both hips\n* Contraindication to performing a biopsy guided by a transrectal ultrasound probe",{"count":538,"type":24},1263,[98],"The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy.\n\nResearch Question P - In patients who are on active surveillance for low to medium risk prostate cancer, I - is the use of regular MRI scans C - compared to current NICE defined standard of care, O - better at detecting cancer progression with less cost to the NHS (fewer PSA tests, biopsies and clinic visits)?\n\nPatients will be allocated in a 1.1 ratio to either MRI scans or the current NICE defined standard. Randomisation will be blocked (random block size) and stratified by MRI visibility of lesions (3 categories \\[ no visible lesion, diffuse changes, discrete visible lesion\\]), cancer Grade Group (GG1, GG2) and time since diagnosis. This study will not be blinded to patients or physicians.",[445],"2026-03-25",{"date":523,"type":50},{"date":545,"type":50},"2024-05-24",{"date":547,"type":24},"2032-06",{"name":56,"class":57},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":18,"sex":19,"minAge":557,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":559,"conditions":560,"keywords":562,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":58},"100600914","white-matter-distortion-and-dementia-biomarkers-in-normal-pressure-hydrocephalus-nph-100600914","NCT07103681","White Matter Distortion and Dementia Biomarkers in Normal Pressure Hydrocephalus (NPH)","Observational Study to Investigate the Effect of White Matter Tract Distortion and Neurodegenerative Biomarkers on Shunt-responsiveness in Idiopathic Normal Pressure Hydrocephalus (iNPH)","OWN-NPH","Group 1 (communicating hydrocephalus):\n\nInclusion Criteria:\n\n* Adult patients \\>60\n* With gait apraxia\n* With or without cognitive impairment\n* Urinary dysfunction\n* Communicating Hydrocephalus\n\nExclusion Criteria:\n\n* Asymptomatic hydrocephalus\n* High pressure-hydrocephalus\n* Serious head injury within 5 years of presentation or a clear secondary cause (e.g. brain infection)\n* History of childhood gait disturbance\n* Clear alternative explanation for symptoms (e.g. Parkinson's disease with limb rigidity, peripheral neuropathy with sensory ataxia, cervical myelopathy).\n* Too frail for shunt surgery\n* Medically unstable (e.g. active angina, respiratory disease, recurrent delirium, active epilepsy).\n* Unable to tolerate MRI brain imaging\n* Unable to have a lumbar puncture\n* Immobile\n* Unable to attend the hospital for study visits\n\nGroup 2 (asymptomatic and non-hydrocepahlus dementia and healthy controls):\n\nInclusion Criteria (Any of the following):\n\n* Healthy Carers\n* Members of the Public\n* Staff of Imperial College\u002FICHT\n* Non-NPH Dementias (including Alzheimer's disease or vascular dementia)\n* Asymptomatic Hydrocephalus\n\nExclusion Criteria:\n\n\\- Unable to attend the hospital for study visits","60 Years",{"count":67,"type":24},"Idiopathic Normal Pressure Hydrocephalus (iNPH) is a progressive condition of the elderly that results in severe disability. iNPH can dramatically respond to Cerebral spinal fluid(CSF)-shunting where excess ventricular fluid is diverted from the brain. Not all patients with iNPH respond to CSF-shunting however. The reasons for this are uncertain.\n\nAim 1: To understand if specific nerve pathways (white matter tracts) that are near ventricles are damaged in patients that respond to shunting as opposed to those that do not.\n\nAim 2: Can we explain shunt non-responsiveness by screening for dementia like illnesses (neurodegeneration) using a large array of methods.\n\nAim 3: To understand whether wearable activity and bed sleep monitors are palatable in a NPH population and to understand if these metrics relate to quality of life.\n\nAim 4: To see whether self-administered digital cognitive assessments can measure improvements pre and post surgery.",[561],"Normal Pressure Hydrocephalus",[563,564,565,566,567,568,569,570,571,572,573],"hydrocephalus","activity monitors","gait impairment","shunt surgery","protokinetic","normal pressure hydrocephalus","shunt-responsiveness","white matter tractography","diffusion tensor imaging","neurodegenerative","NPH","2026-03-24",{"date":52,"type":50},{"date":577,"type":50},"2025-03-25",{"date":579,"type":24},"2029-02",{"name":56,"class":57},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":591,"conditions":592,"keywords":602,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":58},"100550437","cancer-loyalty-card-study-2-clocs-2-100550437","NCT06447064","Cancer Loyalty Card Study 2 (CLOCS-2)","Cancer Loyalty Card Study 2: a Retrospective Observational Case-Control Study","(CLOCS-2)","Inclusion Criteria (ALL):\n\n* Individuals aged \\>18 years of age\n* Individuals must be residing in the United Kingdom at the time of giving informed consent\n* Individuals must be registered with an NHS GP Practice\n* Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer).\n* Individuals must be a primary registered cardholder\\* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team\n* Tesco Clubcard\n* Boots Advantage Card\n* Provision of written informed consent\n* Willing and able to comply with all required study activities\n\n  * The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder from the same household, wants to take part in the study.\n\nExclusion Criteria (ALL):\n\n* Individuals under the age of 18 years\n* Non-UK residents, at the time of giving informed consent\n* Individuals without an eligible loyalty card, or who have no one in their household who has an eligible loyalty card\n* Individuals who are not the primary registered cardholder in their household and where the primary registered loyalty card holder is not willing to join the study, and\u002For where the primary registered cardholder does not make purchases for or on behalf of the individual\n\nExclusion Criteria (CASES):\n\n• Individuals will not be able to join as a case if:\n\n* they have been diagnosed with an eligible cancer type more than 24 months ago (except where the diagnosis was non-melanoma skin cancer).\n* they have received an ineligible cancer diagnosis within the last 6 years except where the diagnosis was non-melanoma skin cancer).\n\nExclusion Criteria (Controls):\n\n• Individuals will not be able to join as a control (Group 2) if:\n\no they have received any cancer diagnosis in the last six years (except where the diagnosis was non-melanoma skin cancer).",{"count":590,"type":24},2900,"Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working.\n\nTherefore, early diagnosis is the most important way to improve cancer outcomes.Most of the cancers usually presents with vague and non-alarming symptoms. Most individuals are diagnosed late when the cancer has already spread, and the prognosis is poor. There are over 200 different types of cancer that can cause many different signs and symptoms. Sometimes symptoms affect specific body areas, such as abdomen or skin. But signs can also be more general, and include weight loss, tiredness (fatigue) or unexplained pain. The type of symptoms varies from person to person.\n\nThe major reasons for not presenting to the GP with symptoms such as these are \"not wanting to waste the GP's time\" and normalisation of these symptoms.\n\nThe persistence of a symptom, social influence and awareness encourage help-seeking behaviours in primary care. However, few believe their symptom(s) might be a sign of cancer. Consequently, people might choose to self-manage their symptoms by using over-the-counter medication, and to seek advice from other sources, (pharmacists, family, internet), rather than a primary care physician.\n\nRATIONALE FOR CURRENT STUDY\n\nAn early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis of cancer can be challenging. Sometimes, the cancer symptoms resemble common illnesses and could resolve with the use of over-the-counter medications and other remedies until they become persistent or debilitating. The present study focuses on ten cancer forms: colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic. Patients diagnosed with the cancers mentioned above often report experiencing vague symptoms (such as abdominal or back pain, indigestion, feeling full etc). They often use over-the-counter medication to manage their symptoms before seeing a doctor.\n\nInformation about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or months earlier and encourage people to seek help sooner from their doctors.",[318,593,594,595,596,597,598,599,600,601],"Colon Cancer","Oesophageal Cancer","Stomach Cancer","Liver Cancer","Bladder Cancer","Uterine Cancer","Vulvar Cancer","Ovarian Cancer","Endometrial Cancer",[600,603,604,605],"Epidemiology","Observational Study","Risk Assessment",{"date":542,"type":50},{"date":608,"type":50},"2026-02-04",{"date":610,"type":24},"2027-04",{"name":56,"class":57},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":25,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":626,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":278},"100528881","grace-evaluating-compression-stockings-in-patients-that-require-extended-duration-pharmacological-thromboprophylaxis-100528881","NCT06166537","GRACE: Evaluating Compression Stockings in Patients That Require Extended Duration Pharmacological Thromboprophylaxis","Graduated Compression Stocking as an Adjunct to Extended Duration Pharmacological Thromboprophylaxis for Venous Thromboembolism Prevention","GRACE","Inclusion Criteria:\n\n* Adults (≥18 years of age)\n* Participants undergoing elective surgery; risk assessed as requiring EDPTP\n\nExclusion Criteria:\n\n* Contraindications to EDPTP or GCS\n* Individuals requiring therapeutic anticoagulation e.g., anticoagulation for previous DVT\n* Known thrombophilia or thrombogenic disorder",{"count":621,"type":24},8608,[98],"Individuals attending the hospital to undergo operations are at risk of developing blood clots in the legs, known as deep vein thrombosis (DVT). A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lungs' ability to move oxygen from the air into the blood and may be life-threatening. This is known as pulmonary embolism (PE). DVT and PE are known collectively as venous thromboembolism or VTE.\n\nThe importance of preventing VTE in surgical patients is widely recognised, with two main strategies used: thinning the blood with regular injections and\u002For tablets and wearing elastic stockings to help stop blood from sitting in the leg veins where it can clot.\n\nEvidence for using elastic stockings to prevent VTE has recently been challenged. Additionally, there is a lack of evidence for the additional benefit of stockings over and above that of blood thinning medications. If stockings were to reduce VTE over and above blood thinning medication, these benefits need to be weighed against the risks and disadvantages of stockings, including discomfort, restricting blood flow to the leg causing blisters and wounds in addition to the cost. If stockings were found not to reduce the risk of clots, they would no longer need to be used in these patients, thus reducing the disadvantages of stockings, and saving the NHS millions of pounds per year.\n\nCertain types of operations (300,000 per year in the UK) are linked with a particularly high risk of VTE, including cancer surgery, surgery in the abdomen and pelvis, and bone (orthopaedic) surgery. In these cases, patients are offered blood thinning medications both during their hospital stay and for a period after they have left the hospital. Furthermore, these patients are offered stockings to wear while in the hospital.\n\nIt is not known if, in patients who receive blood thinning medications both in hospital and after discharge, the addition of wearing stockings whilst in hospital reduces their risk of VTE any further.\n\nThe purpose of this study is to investigate if it is worthwhile using stockings, in addition to blood thinning medication, to reduce blood clots after surgery. People enrolled in the study will be those at the highest risk of VTE and require an extended period of medication to reduce the risk of a blood clot.\n\nA computer will randomly choose one of the below treatments by chance to make the trial fair:\n\nA) Extended duration clot-reducing medicine in addition to stockings B) Extended duration clot-reducing medicine alone\n\nThe surgery and all the other medical care will continue as normal. Everyone in the study will get an ultrasound scan at 21 - 35 days after their operation to check if they have developed a blood clot. This is an additional scan, not routinely performed in the NHS, to make sure that all blood clots are detected at an early stage. Participants will receive a phone call at 7, 21-35 and 90 days after their treatment to see if they have developed a blood clot or had any problems with the treatment.",[243,625],"Surgery",{"date":542,"type":50},{"date":628,"type":50},"2024-04-27",{"date":491,"type":24},{"name":56,"class":57},{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":4,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":638,"targetDuration":4,"studyType":25,"phases":640,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":646,"leadSponsor":648,"locationsCount":4},"100518847","endothelial-cell-activation-and-total-pulmonary-resistance-in-pah-100518847","NCT06035861","Endothelial Cell Activation and Total Pulmonary Resistance in PAH","Investigating the Relationship Between Endothelial Cell Activation and Total Pulmonary Resistance in Pulmonary Artery Hypertension (PAH)","Inclusion Criteria:\n\n1. Subjects aged between 18-75 years old\n2. PAH which is: idiopathic; PAH heritable; PAH associated with connective tissue disease; PAH after ≥ 1 year repair of congenital systemic to pulmonary shunt; or PAH associated with anorexignes or other drugs.\n3. Resting mean pulmonary artery pressure ≥25 mmHg, pulmonary capillary wedge pressure ≤15 mmHg, PVR \\>5 wood units, and normal or reduced cardiac output, as measured by a previous right heart catheterisation (RHC).\n4. Have an insertable FDA\u002FCE cardiac rhythm monitor and pulmonary artery pressure monitor that captures cardiopulmonary haemodynamics and daily activity.\n5. Six-minute walking distance \\>50m at entry\n6. Stable on an unchanged PAH therapeutic regime comprising at least 2 therapies licensed for PAH (any combination of endothelin receptor antagonist, phosphodiesterase inhibitor or prostacyclin analogue) for at least 1 month prior to screening\n7. Subjects willing to be genotyped for genes that influence XBD173 activity\n8. Able to provide written informed consent prior to any study mandated procedures\n9. Contraception: Fertile females (women of childbearing potential) are eligible to participate after a negative highly sensitive pregnancy test, if they are taking a highly effective method of contraception other than the oral contraceptive pill during treatment and until the end of relevant systemic exposure\n\nExclusion Criteria:\n\n1. Unable to provide informed consent and\u002For are non-fluent speakers of the English language\n2. Hypersensitivity to XBD173 or to any of the excipients\n3. Clinically-significant renal disease (confirmed by creatinine clearance \\\u003C30 ml\u002Fmin per 1.73m2)\n4. Clinically-significant liver disease (confirmed by serum transaminases \\>2 times than upper normal limit)\n5. Anaemia confirmed by haemoglobin concentration \\\u003C10 g\u002Fdl\n6. Individuals known to have haemoglobinopathy sickle cell disease, thalassaemia\n7. Hospital admission related to PAH or change in PAH therapy within 3 months prior to screening\n8. History of left-sided heart disease and\u002For clinically significant cardiac disease, including but not limited to any of the following:\n\n   1. Aortic or mitral valve disease (stenosis or regurgitation) defined as greater than mild aortic insufficiency, mild aortic stenosis, mild mitral stenosis, moderate mitral regurgitation\n   2. Mechanical or bioprosthetic cardiac valve\n   3. Pericardial constriction, effusion with tamponade physiology, or abnormal left atrial size.\n   4. Restrictive or congestive cardiomyopathy\n   5. Left ventricular ejection fraction ≤50% (measured in echocardiogram at screening)\n   6. Symptomatic coronary disease\n   7. Significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation\n   8. Acutely decompensated left heart failure within 1 month of screening\n   9. History of untreated obstructive sleep apnoea\n9. Evidence of significant lung disease on high-resolution CT (if available) or recent (performed within 12 months) lung function, where FEV1 \\\u003C 50% predicted and FVC \\\u003C 70% predicted, and DLCO (or TLCO) \\\u003C 50% predicted if any CT abnormalities; judged by the Site Physician\n10. Patients with a history of uncontrolled systemic hypertension\n11. Acute infection (including eye, dental, and skin infections)\n12. Chronic inflammatory disease including HIV, and Hepatitis B\n13. Women of childbearing potential who are pregnant or breastfeeding (if applicable)\n14. Patients who have received an Investigational Medicinal Product (IMP) within 5 half-lives of the last dose of the IMP or 1 month (which ever is greater) before the baseline visit",{"count":639,"type":24},6,[98],"To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension",[643],"Pulmonary Artery Hypertension",{"date":542,"type":50},{"date":224,"type":24},{"date":647,"type":24},"2026-10-31",{"name":56,"class":57},{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":659,"conditions":660,"keywords":665,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":58},"100503894","coronary-flow-during-rapid-heart-rates-100503894","NCT05841199","Coronary Flow During Rapid Heart Rates","Coronary Epicardial and Microcirculatory Determinants of Ventricular Tachycardia Tolerability","VT flow","Inclusion Criteria:\n\n* Able to give valid consent\n* Referred for coronary angiography or coronary angioplasty\n* Suitable for percutaneous physiological interrogation and PCI when clinically indicated\n\nExclusion Criteria:\n\n* Unable to give valid consent\n* Pregnant or breastfeeding women\n* Unstable coronary artery disease (acute coronary syndrome)\n* Severe multivessel coronary artery disease suitable for coronary artery bypass grafting\n* Severe heart valve disease\n* Severe (NYHA IV) heart failure",{"count":658,"type":24},70,"The goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (VT) is tolerated. The main questions it aims to answer are:\n\n1. What impact does coronary artery disease have on the ability for a patient to tolerate VT?\n2. Does treatment of coronary artery disease with stents improve the tolerability of VT?\n\nParticipants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.",[661,662,130,663,664],"Ventricular Tachycardia","Coronary Artery Disease","Coronary Microvascular Dysfunction","Coronary Microvascular Disease",[661,662,130,663,664,666,667],"Percutaneous Coronary Intervention","Implantable Cardioverter Defibrillator",{"date":52,"type":50},{"date":670,"type":50},"2023-08-01",{"date":672,"type":24},"2026-06-02",{"name":56,"class":57},{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":678,"acronym":679,"eligibilityCriteria":680,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":681,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":683,"conditions":684,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":690,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":695,"locationsCount":58},"100440187","evaluation-of-high-dose-prednisolone-pharmacokinetics-in-the-acute-and-chronic-setting-100440187","NCT05012033","Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","EHD-Pred PK","Inclusion Criteria:\n\n* Aged 18 - 75 years\n* Male or female\n* Participants who are otherwise healthy enough to participate, as determined by pre-study medical history\n* Participants who are able and willing to give written informed consent to participate in the study\n* Group A only: Patients requiring acute (\\\u003C5 days) high dose (minimum 30mg) oral prednisolone therapy for antiinflammatory purposes in either an inpatient or outpatient setting.\n* Group B only: Minimum of 1 month duration of high dose prednisolone (\\>30mg) if in the chronic use group.\n* Group C only: Patients started on high dose methylprednisolone (\\>3 day course) or prolonged courses of dexamethasone.\n\nExclusion Criteria:\n\n* Participants with a diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Unable to give informed consent.\n* Taking supplements or herbal medications that the participant is unwilling or unable to stop prior to and during the study period e.g. St John's Wort (may decrease prednisolone levels), Cat's claw, Echinacea (immunomodulatory properties).\n* Currently taking medications that alter CYP3A4 metabolism of glucocorticoids that the participant is unwilling or unable to stop prior to and during the study period e.g. phenytoin, phenobarbital, rifampicin, rifabutin, carbamazepine, primidone, aminogluethimide, itraconazole, ketoconazole, ciclosporin or ritonavir.\n* Pregnancy. Females of child-bearing age will be asked to provide a urine sample for a pregnancy test at each visit.\n* History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.",{"count":682,"type":24},120,"This is a pilot study to investigate serum prednisolone profiles in:\n\n* Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting.\n* Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone.\n\nThe study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone.\n\nThe study aims to measure prednisolone levels at a number of time points to investigate serum profile differences in those receiving prednisolone acutely compared with longer term steroid use. Further samples will be taken to characterise additional metabolic changes.",[685,686,687,688,689],"Thyroid Eye Disease","Vasculitis","COPD Exacerbation Acute","Asthma","Inflammatory Disease",{"date":52,"type":50},{"date":692,"type":50},"2023-04-12",{"date":694,"type":24},"2030-12-31",{"name":56,"class":57},""]